Cite
MLA Citation
M.C. Pietanza et al.. “7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC).” European journal of cancer, vol. 51, n.d., pp. S712–. http://access.bl.uk/ark:/81055/vdc_100030687872.0x000062